AcelRx sells DSUVIA/DZUVEO assets to Vertical Pharma for up to $116.5M milestones plus royalties

TALPHERA, INC.

AcelRx to sell DSUVIA/DZUVEO sufentanil tablet to Vertical Pharma; gets up to $116.5M in sales milestones and 15% net sales royalty.
75% of DoD net sales under marketing agreement; rights revert if Buyer fails to commercialize by July 1, 2023.
Aguettant amendments: EUR 1.5M payment to AcelRx, termination of sales milestones, and supply restructuring.
Terminates Catalent site readiness and commercial supply agreements; equipment to be removed from Catalent's site.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.